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Abstract
Background All proposed deﬁnitions of sarcopenia include the measurement of muscle mass, but the techniques and
threshold values used vary. Indeed, the literature does not establish consensus on the best technique for measuring lean body
mass. Thus, the objective measurement of sarcopenia is hampered by limitations intrinsic to assessment tools. The aim of this
study was to review the methods to assess muscle mass and to reach consensus on the development of a reference standard.
Methods Literature reviews were performed by members of the European Society for Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis working group on frailty and sarcopenia. Face-to-face meetings were organized for the whole
group to make amendments and discuss further recommendations.
Results A wide range of techniques can be used to assess muscle mass. Cost, availability, and ease of use can determine
whether the techniques are better suited to clinical practice or are more useful for research. No one technique subserves
all requirements but dual energy X-ray absorptiometry could be considered as a reference standard (but not a gold standard)
for measuring muscle lean body mass.
Conclusions Based on the feasibility, accuracy, safety, and low cost, dual energy X-ray absorptiometry can be considered as
the reference standard for measuring muscle mass.
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Background
The term sarcopenia was ﬁrst used by Rosenberg et al. in
19891 to refer to a progressive loss of skeletal muscle mass
with advancing age. Baumgartner, deﬁned sarcopenia as ap-
pendicular skeletal muscle mass (kilogram)/height2(metre2)
being less than two standard deviations below the mean of
a reference group.
2
Since then, the conceptual deﬁnition of
sarcopenia has expanded to include impaired muscle
strength and/or physical performance. In turning a concep-
tual deﬁnition to an operational deﬁnition, several have been
proposed,2–10 but no consensus has yet been reached. The
multidimensional nature of sarcopenia implies that its do-
mains should be objectively assessed.
11,12
Therefore, valid,
standardized, reliable, accurate, and cost-effective tools are
necessary for the identiﬁcation of sarcopenia.13,14 Currently,
all the proposed deﬁnitions include the measurement of
muscle mass but the techniques used to assess it vary. In re-
cent years, four main techniques have been commonly used
to estimate muscle mass: bioelectric impedance (BIA), dual
energy X-ray absorptiometry (DXA), computed tomography
(CT), and magnetic resonance imaging (MRI) to replace an-
thropometry.15–17 In addition to these, several emerging
techniques for the assessment of muscle mass are now avail-
able. Each rely on different technologies and assess different
aspects of muscle mass (e.g. total body muscle mass, appen-
dicular muscle mass, or mid-thigh muscle cross-sectional
area) (Figure 1). At the organizational level, the body can be
separated into chemical or anatomical distinct compart-
ments. The 2-compartment model divides the body weight
into fat mass and fat free mass or FFM.18 Body composition
techniques are based on these organizational levels. There-
fore, the objective measurement of sarcopenia is hampered
by limitations intrinsic to assessment tools.11,19 From a clini-
cal and epidemiological point of view, it is important to have
a consensual technique. The use of different diagnostic
methods may lead to different prevalence of sarcopenia
and may therefore have signiﬁcant consequences on preven-
tive or therapeutic strategies.
Matiegka reported in 1921 what was to become a classic
anthropometric approach to quantifying skeletal muscle
mass.20 Matiegka’s method divided body weight into four
parts: skeleton, skeletal muscle, skin plus subcutaneous adi-
pose tissue, and the remainder. Others that followed
Matiegka were limited by a lack of reference standards for
skeletal muscle mass measurement until the introduction of
CT by Hounsﬁeld.21 After this phase, CT, MRI, and DXA were
being used to measure muscle mass (so a more speciﬁc mus-
cle assessment compared with the general FFM). Subse-
quently, BIA equations were developed to predict muscle
mass (instead of FFM). The availability of DXA systems, with
modest scan cost, low radiation exposure, short scan time,
and extensive information provided from a whole body scan
makes this approach the most widely used in sarcopenia re-
search at the present time.17,22 Indeed, imaging methods
such as MRI and CT are expensive methods and are not ac-
cessible to the majority of clinicians and researchers.23 Never-
theless, the literature has not established consensus on the
‘best’ technique to measure muscle mass. Because of the
need for consensus and standardization for both clinicians
and researchers, the widely used techniques measuring mus-
cle mass are reviewed in the succeeding text and recommen-
dations derived therefrom.
Methods
The European Society for Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis working group on frailty
and sarcopenia consists of clinical scientists and experts in
the ﬁeld of musculoskeletal diseases. Different members of
Figure 1 Body compartments based on reference man.
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the working group were asked to prepare a literature review
on the role of lean mass measurement in the assessment of
sarcopenia (M.C.), the measurement of Lean Body Mass with
DXA (M.V. and K.E.), with bioimpedance (S.M.), and with
emerging techniques (R.F.). The topic ‘how to produce refer-
ence standards for the assessment of Lean Body Mass’ was
also discussed (E.D.). Each member prepared a list of the
most important papers based on their literature search and
made a set of preliminary recommendations. For each item,
a complete literature search was performed to identify new
or additional randomized controlled trials and systematic
reviews/meta-analysis, if any, not used in the existing guide-
lines. The MEDLINE (pubmed) database was searched using
the name of each technique for measuring body composition
as a search term, together ‘with lean body mass’, limiting re-
sults to ‘humans’, ‘randomized controlled trials’, ‘meta-
analysis’, ‘systematic reviews’, and ‘guidelines’. A similar
search was adapted for the Embase database, and each item
was also searched in the Cochrane Database of systematic re-
views. The reference list of relevant retrieved articles was
hand-searched for additional resources when member of
the working group were interrogated for their knowledge
on articles or congress abstract in press. A free web search
was also performed and considered. Searches were per-
formed from the year 2000 and updated until September
2016, with the additional evidence constantly provided to
the working group members for selection of the best evi-
dence according to the panel.
The subsequent step was a face-to-face meeting for the
whole group to make amendments and discuss further rec-
ommendations. The plan of the manuscript was also
discussed and shared conclusions were reached.
Results
First, it seems important to clarify several terms. Skeletal
muscle mass is the largest component of adipose tissue–free
body mass in humans.
24
Lean mass also known as lean body
mass is a fat-free and bone mineral–free component that in-
cludes muscle and other components such as skin, tendons,
and connective tissues (Figure 2). Appendicular lean soft tis-
sue is the sum of lean soft tissue from both arms and legs.26
A large proportion of total-body skeletal muscle is found in
the extremities, and a large proportion of appendicular lean
soft tissue is skeletal muscle (Figure 1).25
Measurement of lean body mass and
muscle mass with imaging techniques
Dual energy X-ray absorptiometry
Dual energy X-ray absorptiometry is the most widespread
technique for measuring body composition.27 DXA uses two
different energy spectra to differentiate two materials: either
bone or soft tissue, which is the basis for the measurement of
bone mineral density (BMD) and content or lean soft tissue
mass and fat mass in locations where bone is absent. Taken
together, DXA provides an estimate of three body compart-
ments, that is, lean, bone, and fat. At bone locations, lean
and soft tissue are interpolated from the surroundings. These
measurements can be performed for the whole body and for
several regions (e.g. trunk, arms, and legs).28,29 The principle
of using DXA for measurement of body composition is based
on the notion that when a beam of X-rays is passed through a
complex material, the beam is attenuated in proportion to
the composition and thickness of the material. The use of
two different energy spectra is the basis to separately quan-
tify the amount of bone mineral and soft tissue or of fat
and lean mass. Lean soft tissue and adipose tissue are mostly
comprised by water and organic compounds, which restrict
the ﬂux of X-rays less than bone.15,30 DXA is able to assess to-
tal body lean soft tissue mass (which includes skeletal muscle
mass as well as the mass of all other organs) and appendicu-
lar lean soft tissue mass (i.e. an estimate of the muscle mass
contained in the limbs, which represents about 75% total
body skeletal muscle mass).27
Appendicular lean soft tissue mass measured by DXA is
highly correlated with both MRI (r = 0.88; P < 0.001) and
CT (r = 0.77–0.95, P < 0.0001) measures of skeletal muscle
volume.25,31–39 In vivo precision errors depend on DXA equip-
ment, population, local versus whole body measurements,
age, and degree of obesity. Recently published values for ap-
pendicular lean soft tissue mass range from below 1–3.0%.
Higher errors of 4% were reported for bilateral muscle mass
of the arms. Precision of DXA is high.40 According to
Hangartner, the precision error, expressed in %CV, for lean
body mass was 1.2%40.
Strengths and weakness of the DXA technique are summa-
rized in Table 1.
Figure 2 Relations between appendicular lean soft tissue (ALST) and to-
tal-body skeletal muscle (SM) mass.25
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Note that DXA half-body analysis in obese subjects appears
to be closely comparable to whole-body analysis for fat mass,
non-bone lean mass, and percent fat, though there are no
data on the comparability at appendicular sites.
43
Dual energy X-ray absorptiometry is a candidate for pro-
viding a reference technology for assessing lean mass (as a
proxy of muscle mass) and body composition in research
and clinical practice. There is however a need for standardiza-
tion. Standardization can be approached using phantoms or
humans. Existing body composition phantoms are not anthro-
pometric and cannot be used as absolute reference standards
for soft-tissue composition. Therefore, a recent International
Society for Clinical Densitometry report concluded that ‘No
phantom has been identiﬁed to remove systematic difference
in body composition when comparing in vivo results across
manufacturers’. As a consequence, ‘an in vivo cross-
calibration study is necessary when comparing in vivo results
across manufacturers’.41
Still for a unique standardization, the use of phantoms
would be preferable because an in vivo cross calibration is in-
ﬂuenced by age, gender, ethnicity, healthy versus diseased
subjects, and so on.
44
Ideally, the calibration materials and
equations used to derive lean mass should be standardized
across manufacturers or cross-manufacturer algorithms
should be developed by industry to standardize the output.
It is also important to standardize the local regions of inter-
est, such as trunk, arms, and legs, which are signiﬁcantly dif-
ferent across manufacturers.45,46
Computed tomography
Computed tomography (CT) was the ﬁrst method introduced
that could quantify regional skeletal muscle mass with high ac-
curacy.17 CT determines the cross-sectional distribution of the
X-ray absorption coefﬁcient, which after normalization to the
absorption of air and water is called CT value and measured
in Hounsﬁeld units (HU). CT slices of predeﬁned width can be
analysed for different tissues, using manual segmentation or
automated software. For example, muscle area, or in case of
the analysis of a stack of images, volume of individual muscles,
or a group of muscles can be determined. By deﬁnition, the HU
value of air is1000 and of water 0. Bone, skeletal muscle, ad-
ipose tissue, and visceral organs have speciﬁc Hounsﬁeld unit
ranges, allowing for their identiﬁcation in the cross-sectional
images. The tissue area/volume (cm2/cm3) of the cross-sec-
tional/stack of images is subsequently calculated by multiply-
ing the number of pixels/voxels for a given tissue by the
pixel area/voxel size. Muscle mass can be derived by multiply-
ing muscle volume by 1.04 that is the assumed constant den-
sity (kg/cm3) of adipose tissue-free skeletal muscle.
47
Compared with DXA, CT is a 3D imaging technique that al-
lows for quantitative assessment of individual muscles. More-
over, the muscle tissue composition can be quantiﬁed, either
by separate segmentation of muscle and adipose tissue or by
analysing muscle density, that is, the HU distribution within
the segmented muscle.48
In vivo precision errors for muscle volume or mass mea-
surements have rarely been reported, but reanalysis preci-
sion errors are low due to its high resolution (typically 50
microns or less).
49
This is important because with advanced
3D imaging, precision of muscle area and mass depend more
on image segmentation than on repositioning. For reanalysis,
intraclass correlation coefﬁcients (ICC) between 0.98 and
1.00 (P < 0.001)50 in quantifying both adipose tissue and
muscle mass
51
were reported.
Major disadvantages of CT are limited access to the radio-
logical departments that operate it and considerably higher
cost and radiation exposure than for DXA. Despite calibration
of HU to water, calibration of CT across models and scanner
manufacturers is still required when comparing scans from
different devices. In addition, very obese patients may not
ﬁt into the scanner and image quality will be poor. Also, the
operation of a CT scanner requires highly qualiﬁed personnel.
The widespread implementation of CT imaging in the ﬁeld of
sarcopenia has been hampered by the previously mentioned
Table 1 Strengths and weakness of measuring muscle mass by dual energy X-ray absorptiometry
Strengths Weaknesses
Non-invasive with small doses of radiation (<1 μSv
for whole-body scans).41
Projectional technique, individual muscles cannot be assessed separately.
Relatively cheap, compared with CT scan or MRI. Not portable, which may preclude its use in large-scale epidemiological studies
and studies in the home setting.
Rapid Availability is limited in some care settings.
Allows measurement of three body compartments. Body thickness and abnormalities in hydration status (e.g. water retention, heart,
kidney, or liver failure) can affect muscle mass measure.42
Low precision errors Very tall and very obese people cannot be measured.
Cannot quantify fatty inﬁltration of muscle. It is a bias in the diagnosis of
sarcopenia obesity.
Does not measure skeletal muscle mass in non-limb regions of the body (e.g.
trunk).
Several devices and several software packages and software versions resulting in
different results.
CT, computed tomography; MRI, magnetic resonance imaging.
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limitations. An alternative to whole body clinical CT scanners
may be the use of CT scanners dedicated and limited to pe-
ripheral investigations, which is cheaper and has lower expo-
sure to radiation is presently better suited for small-scale
research studies in which accurate measurements of muscle
quantity and quality are needed.
Magnetic resonance imaging
The introduction of MRI in the 1980s expanded the initial use
of CT as a means of developing 3-dimensional images of skel-
etal muscle, adipose tissue, and other organs. This develop-
ment is usually referred to as structural or anatomic
imaging.17 The resolution is very high, and MRI is safe with-
out any radiation exposure. With the advancement of the
MRI technique, the time for reliable image acquisition has de-
creased signiﬁcantly. In addition, most modern MRI scanners
can accommodate obese subjects. Limitations in the use of
MRI in clinical and research settings are largely related to
the high cost, the technical expertise required for analysis,
and the effect of respiratory motion on image quality for
whole-body assessments. Multiple slices are required to as-
sess the composition of the total body, including total body
skeletal muscle mass.52 Finally, the existence of multiple pro-
tocols for data acquisition impacts the standardization of this
technique for the study of muscle mass.42 Bearing all these
considerations in mind, MRI is presently better suited for
small-scale research studies in which accurate measurements
of muscle quantity and quality are needed.
Estimation of lean body mass and muscle mass
with bioimpedance analysis
Bioimpedance analysis (BIA) was pioneered in the 1950s and
1960s by Hoffer, Nyboer, and Thomasset.53–55 Since then, BIA
has become a broadly applied approach used in body compo-
sition measurements and healthcare assessment systems.
56
BIA is based on the notion that tissues rich in water and
electrolytes (i.e. skeletal muscle) are less resistant to the
passage of an electrical current than lipid-rich adipose tissue
(i.e. bone).17,57 All BIA systems exploit these tissue-speciﬁc
conductivity differences to quantify body-compartments. In
bioimpedance measurements, the human body is divided into
ﬁve inhomogeneous segments, two for the upper limbs, two
for the lower limbs, and one for the trunk.
56
Many available
BIA system designs range from single to multiple frequency,
employ contact or gel electrodes, and measure whole-body
electrical or segmental pathways.
17
All BIA systems measure
impedance and/or its two components, resistance (caused
by the total water across the body) and reactance (due to ca-
pacitance of cell membrane). These electrical measurements
in turn can be incorporated into body composition prediction
equations that are population speciﬁc.17 Advantages and dis-
advantages of BIA are listed in Table 2.
Due to the large number of factors conditioning BIA reli-
ability: instrument related factors (i.e. intra-instrumental
and inter-instrumental variability, electrode quality, and
electrode positioning), technician-related factors (i.e. intra-
operator and inter-operator variability), subject-related fac-
tors (i.e. subject preparation such as position, overnight fast
or empty bladder, body temperature, skin conductibility,
age, and ethnicity), and environment-related factors (i.e. tem-
perature), BIA does not seem to be ideal for measuring lean
body mass, mainly due to the problem of the individual pre-
diction error. A recent study showed that the reliability of BIA
to assess appendicular lean mass was high, with an ICC of
0.89 (95%CI: 0.86–0.92) when performed by the same opera-
tor, and an ICC of 0.77 (95%CI: 0.72–0.82) when performed
by two different operators. Nevertheless, in this study, agree-
ment between appendicular lean mass assessed by DXA and
predicted by BIA was low [ICC = 0.37 (95%CI: 0.25–0.48)].57
There is a potential large prediction error on the individual
level with BIA. Indeed, there is a systematic positive bias with
an overall underestimation of lean body mass measurements
by BIA.
60
It is, however, one of the few alternatives when
other more precise techniques are not feasible.
Emerging techniques for the
assessment of muscle mass
Because of the limitations of the current techniques to assess
lean mass (cost, accuracy, feasibility), new techniques have
Table 2 Strengths and weakness of estimating muscle mass by BIA
Strengths Weaknesses
Inexpensive and easy to use4 Measurements are sensitive to subjects’ conditions such as hydration, recent
activity, and time being horizontal58,59
Precise measurement of body resistance
and reactance
Large individual prediction error for estimated muscle mass
Safe and non-invasive method17 Need of age, gender, and ethnic-speciﬁc prediction equation to estimate muscle mass
Portable tool and can be used in
most environments57
No BIA-speciﬁc equations validated in patients with extreme BMI
Does not require highly trained personnel Multiple devices with different body composition outputs
BIA, bioelectrical impedance analysis; BMI, body mass index.
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appeared. Among these techniques, creatine (methyl-d3)
dilution (D3-creatine) is of some interest.61
Creatine is present predominantly (∼95%) in skeletal mus-
cle. Roughly 2% of creatine is converted to creatinine per day,
via an irreversible, non-enzymatic mechanism, so that ∼2 g
per day of creatine are replaced in the whole body. Based
on the assumption that conversion of creatine to creatinine
is constant among and within subjects, the daily excretion
rate of creatinine has been used as a metric of whole body
creatine pool size.62 Reviews of this method show that a rel-
atively broad range of muscle mass per gram of urinary creat-
inine (17–22 kg) has been used to estimate muscle mass,
leading to large variability in muscle mass estimates between
studies, and further suggest limitations to this method in cer-
tain patient groups, such as those affected by renal failure.63
Furthermore, there are inherent limitations to this method
(in addition to the problem of inaccurate 24-h urine collec-
tions): pH and temperature affect the non-enzymatic conver-
sion rate of creatine to creatinine, and there is degradation
and metabolic removal of creatinine in the body, so all creat-
inine produced is not excreted in the urine.64 The results are
also dependent on the intake of meat that increases the ex-
cretion of creatinine. Thus, accurate assessment requires a
meat-free diet for about 1–2 weeks.
Electrical impedance myography is a non-invasive, painless
approach to muscle assessment based on the application and
measurement of high-frequency, low-intensity electrical cur-
rent. Measurements are made over a small area of interest,
with energy being applied to the body and the resultant
surface patterns analysed. Several parameters are obtained,
including the tissue’s reactance, resistance, and phase angle
that can provide a quantitative measure of muscle
condition.65 The central concept of electrical impedance
myography is that skeletal muscle can be modelled as a net-
work of resistors and capacitors. The intracellular and extra-
cellular matrices of muscle tissue act as resistors, and any
atrophy that reduces the cross-sectional area of muscle tissue
would be expected to increase the resistance. The lipid bilay-
ers that constitute muscle membranes act as capacitors, and
as muscle atrophies, the cumulative capacitance of the mus-
cle membranes increases.66 Electrical current is used, and the
output is a set of quantitative parameters describing muscle
state, with presently little emphasis on imaging (though this
remains possible).67
Ultrasound is an imaging technique that can determine
thickness and cross-sectional areas of superﬁcial muscles. In
particular, with ultrasound analysis, it is possible to measure
key parameters of muscle architecture, such as muscle vol-
ume, fascicle length, and pennation angle. Fascicle length,
which is an estimate of muscle ﬁbre length, is deﬁned as the
length of a line coincident with the fascicle between the deep
and superﬁcial aponeuroses. Fascicle length indicates the
range of lengths over which the muscle is capable of actively
producing force, known as the excursion potential. Pennation
angle represents the angle of the muscle ﬁbres that constitute
a muscle fascicle relative to the force-generating axis, and di-
rectly affects both the force production and the excursion;
larger angles of pennation limiting the excursion potential.68
Ultrasound has the advantage of being portable and involves
no ionizing radiation. A number of studies have conﬁrmed
the reliability of this technique for measuring the size of the
quadriceps muscle in health. For example, an ICC of 0.97
(95%CI: 0.92–0.99) was found for the test–retest reliability
of ultrasound at the rectus femoris.69 However, a major prob-
lem is the impact of the applied pressure on the probe on the
measurement result. Even though, this method of body com-
position analysis is not widely used for sarcopenia screening
and staging,70,71 in the near future, it may become a valid
method to assess muscle in different settings.72
Biomarkers are another way to assess muscle mass. Previ-
ous studies have shown that the serum levels of the Collagen
type III propeptide correlate well with whole body lean
mass.
73
As do the circulating levels of Collagen type VI pep-
tides containing the IC6 epitope.74 Nedergaard et al. shown
that the anabolic response to reloading the following
immobilization was inversely related to the levels of the
matrix-metalloproteinase-generated Collagen type VI frag-
ment C6M.74Both Collagen types III and VI are known to be
important constituents of the extracellular matrix of skeletal
muscle.75,76 Therefore, fragments produced during muscle
tissue turnover may be correlated with lean body mass.73
Dysregulation of microRNAs may also contribute to reduced
muscle plasticity with aging.77
Towards a reference standard
The considerations above indicate that no currently available
technique serves all the requirements for the measurement
of muscle mass. Each has limitations and in particular, there
is a dearth of information on accuracy. Moreover, none are
fully standardized. Thus, there is at present no gold standard.
Notwithstanding, there is need to develop a reference stan-
dard against which alternative techniques can be evaluated.
Major disadvantages of CT are limited access to the radio-
logical departments that operate it, considerably higher cost
and radiation exposure than for DXA. Limitations in the use
of MRI in clinical and research settings are largely related to
the high cost and the technical expertise required for analysis
and limited access. The main challenge for BIA is the availabil-
ity of population-speciﬁc equations to predict lean mass (or
other body composition parameters) according to the
reference standard used to validate the BIA equation. In fact,
several good equations are available; but many clinicians rely
on the outputs generated by the device itself (which is
using an in-built equation, most often kept ‘hidden’ by the
manufacturer).
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These considerations suggest that, despite many
limitations,78 DXA may be considered the current reference
technique for assessing muscle mass and body composition
in research and clinical practice. An important reason for pre-
ferring DXA above BIA is that DXA measures body composi-
tion on an individual level, whilst BIA uses a prediction
equation (so it estimates muscle instead of measuring it),
and is hampered by large prediction error on the individual
level. Also, BIA standardization will be more complicated
than DXA standardization due to the multitude of available
BIA devices.
In addition, DXA has been used successfully to estimate
skeletal muscle mass as part of RCT’s.79–81 Currently, it is
the preferred and effective measurement technique in this
context.
To ensure the accuracy of DXA measurement, standardiza-
tion is needed. Calibration materials and equations used to
derive lean mass should be standardized across manufac-
turers. An important item on the research agenda is to stan-
dardize the local regions of Interest, such as trunk, arms, legs,
that are signiﬁcantly different across manufacturers. Finally,
consensus is required in adopting a reference population in
much the same way as has been achieved for the use of
DXA in osteoporosis.82
It is important to note that the adoption of a
reference standard does not proscribe the use of any of
the techniques in clinical research or clinical practice. Indeed,
this is to be encouraged. There is a useful analogy with
the use of BMD in the assessment of osteoporosis. The
reference standard is BMD at the femoral neck,83 but in clin-
ical research and clinical practice many assessment tools are
widely used (e.g. BMD at other skeletal sites, CT, quantitative
ultrasound, and trabecular bone score). The caveat is
that where the opportunity arises BMD should also be
reported using the reference technology applied to a
reference population and is now a requirement in many of
the bone journals.
The adoption of DXA as a reference standard with a de-
ﬁned normal range provides a platform on which the perfor-
mance characteristics of less well-established and new
methodologies can be compared. It also permits comparisons
between studies and between countries.
Different indices to express lean body
mass
Skeletal muscle index (SMI) is a measure to express lean
mass in relation to height or weight. Unfortunately, the
common use and terminology of SMI is inconsistent.84 It
is either deﬁned as appendicular skeletal muscle mass
divided by height2 and measured in kg/m2
2
or as skeletal
muscle mass divided by body mass × 100, which is a
unitless index,
24
although some authors distinguish them
as appendicular lean mass/ht2 and SMI.85 SMI can be
derived from BIA or from DXA measurements. Both SMI
deﬁnitions have previously been shown to predict disability
and functional limitations in large, epidemiologic studies of
older adults.8,86,87 However, the classiﬁcation of community-
dwelling older adults as sarcopenic or non-sarcopenic
differed markedly for the two deﬁnitions.85 The weight
based SMI classiﬁed signiﬁcantly more community-dwelling
older adults as sarcopenic than the height based index, a
trend more deep-seated in men than women. More
recently even a third deﬁnition, the application lifecycle
management/BMI index was proposed.8,85 Due to the
discrepancies observed, a clearer terminology should be
developed, and it seems necessary to use that index that
can best describe the associations between muscle mass
and important clinical outcomes in epidemiological
studies.
Discussion
More and more attention is being paid to the measurement
of muscle mass in different contexts and populations. Over
the last few years, sarcopenia has come into the spotlight
in biogerontology and research. In this context, the estab-
lishment of an international consensus on an accurate, reli-
able, and cost-effective method to assess muscle mass
across research and clinical settings is of utmost importance.
As shown above, a wide range of techniques can be used to
estimate or measure muscle mass.9 Cost, availability, and
ease of use can determine whether the techniques are
better suited to clinical practice or are more useful for
research. Reference standards are well established in the
pharmaceutical industry and laboratory settings, and refer
to ‘a universal reference method that performs equally
and reproducibly between platforms’. In the ﬁeld of muscu-
loskeletal disorder, there is no reference method for mea-
suring muscle mass, and this paper aims to begin ﬁlling
this gap.
A muscle mass measure should provide a diagnostic crite-
rion for sarcopenia, prognostic information, and a baseline
to monitor the natural history of treated and untreated pa-
tients. To obtain a complete picture of body composition, a
4-component model comprising total body water, protein,
mineral, and fat mass is required. However, this is a highly
intensive and costly procedure and does not enable
the measurement of muscle mass speciﬁcally.88 As a 3-
component model (combining protein and minerals into
‘solids’), DXA is superior to standard densitometry (which
differentiates only between fat mass and fat-free mass),
and has been widely adopted.9 DXA is primarily used for
diagnosing osteoporosis, assessing fracture risk, and
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monitoring therapy. However, given its ability to measure
soft tissue mass of the arms and legs as an accurate and
precise assessment of appendicular skeletal muscle mass,
DXA has been suggested as a potential tool for diagnosing
sarcopenia.4 Operationally, DXA-based deﬁnitions for
sarcopenia have generally used appendicular skeletal muscle
mass divided by body height squared.89 However, more re-
cently, the ratio of appendicular skeletal muscle mass di-
vided by BMI is also being suggested.8 Regardless of the
choice of outcome measure for clinical trials of sarcopenia,
precise methodology is available for the assessment of lean
mass, and this may serve as a key deﬁning characteristic of
sarcopenia in clinical practice.9
DXA has now largely met that unmet need by providing a
measure of muscle mass at relatively low cost and with min-
imal radiation exposure.32 Thus, it could be considered as the
reference standard for measuring muscle mass and for pro-
viding a platform on which the performance characteristics
of less well-established and new methodologies can be
compared.
We conclude that the adoption of reference standards will
contribute to the development of the assessment of muscle
mass, in order to make studies comparable and to improve
the diagnosis and treatment of sarcopenia, but also to mon-
itor the development of muscle mass in healthy, athletic,
and sick subjects. In this sense, DXA provides a precise mea-
sure of lean mass, but further standardization is needed to
ensure that the assessment and cut points are used accu-
rately on all makes and models of DXA systems. Thus, the Eu-
ropean Society for Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis working group on frailty
and sarcopenia state that DXA is the gold standard for the
measurement of muscle mass.
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